Omalizumab, sold under the trade name Xolair, is a humanized antibody
originally designed to reduce sensitivity to inhaled or ingested allergens,
especially in ...
A Xolair vial contains 202.5 mg of Omalizumab, 145.5 mg ... After SC
administration, Omalizumab is absorbed with an average absolute bioavailability
Feb 15, 2015 ... Omalizumab injection may cause serious or life-threatening allergic reactions.
You may experience an allergic reaction immediately after ...
XOLAIR® (omalizumab) for injection, for subcutaneous use ..... For injection: 150
mg of omalizumab as lyophilized, sterile powder in a single-use 5 mL vial.
Clinical Therapeutics from The New England Journal of Medicine — Omalizumab
Information about omalizumab (Xolair), an injectable drug prescribed to treat
asthma that is not adequately controlled with inhaled steroids.
Omalizumab has demonstrated efficacy in children, adults, and adolescents with
uncontrolled moderate to severe allergic asthma and allergic rhinitis.
Omalizumab as Initial Therapy for a Patient on Prednisone and Having Mild
Bilateral Wheezing. Michael A. Kaliner, MD, Medscape, 2005. MEDLINE
Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost
.... The fall exacerbation rate was significantly lower in the omalizumab versus ...
Professional guide for Omalizumab. Includes: pharmacology, pharmacokinetics,
contraindications, interactions, adverse reactions and more.